In 2021, QIAGEN started a cooperation with the Californian forensics specialist to sell the Verogen product portfolio. QIAGEN announced on Monday that the acquisition will strengthen its position in technologies for forensic laboratories and criminal investigators. The DAX group marketed the first commercial kits for purifying DNA from forensic case samples in the late 1990s and claims to be a leader in the field of personal identification and forensics.
As a result of the acquisition, which will be paid for in cash from existing reserves, QIAGEN currently expects additional sales of approximately $20 million this year, building on approximately $5 million in sales from a distribution agreement last year. However, due to planned investments in marketing and the development of the product portfolio, the acquisition should dilute the adjusted earnings per share in 2023 by around three cents and have a neutral effect in the coming year.
QIAGEN shares temporarily fell by 0.30 percent to EUR 46.76 via XETRA.
Frankfurt (Reuters)
Leverage must be between 2 and 20
No data
More news about QIAGEN NV
Image sources: Dennis Diatel / Shutterstock.com, QIAGEN